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Introduction {#jcsm12349-sec-0005}
============

Sarcopenia, characterized by low muscle mass, is independently associated with elevated mortality in end‐stage liver disease (ESLD) patients.[1](#jcsm12349-bib-0001){ref-type="ref"}, [2](#jcsm12349-bib-0002){ref-type="ref"}, [3](#jcsm12349-bib-0003){ref-type="ref"}, [4](#jcsm12349-bib-0004){ref-type="ref"} Higher waitlist mortality and longer hospital stay following liver transplantation (LT) have been reported in patients with ESLD and sarcopenia.[5](#jcsm12349-bib-0005){ref-type="ref"} In most studies, sarcopenia was more prevalent in male patients with cirrhosis compared with female patients.[1](#jcsm12349-bib-0001){ref-type="ref"}, [5](#jcsm12349-bib-0005){ref-type="ref"}, [6](#jcsm12349-bib-0006){ref-type="ref"}

Various approaches to assess body composition such as body mass index (BMI, kg/m^2^), bioelectrical impedance analysis, and dual‐energy X‐ray absorptiometry[6](#jcsm12349-bib-0006){ref-type="ref"}, [7](#jcsm12349-bib-0007){ref-type="ref"} have been used to patients with cirrhosis. Non‐invasive imaging with computed tomography (CT) has been applied as a precise technique for muscle and adipose tissue quantification.[8](#jcsm12349-bib-0008){ref-type="ref"} Diagnostic CT imaging is a routine part of LT assessment in most LT centres, to screen for hepatocellular carcinoma (HCC) and evaluate the vascular and biliary anatomy.

A comprehensive definition of sarcopenia has been recently developed in a population of cirrhotic patients listed for LT at four North American LT centres.[1](#jcsm12349-bib-0001){ref-type="ref"} CT‐determined skeletal muscle index (SMI) was used to discriminate waitlist mortality in these patients.[1](#jcsm12349-bib-0001){ref-type="ref"} SMI in a single CT image at the level of the third lumbar vertebrate (L3) is a reliable and valid representative of whole body muscle mass.[8](#jcsm12349-bib-0008){ref-type="ref"}, [9](#jcsm12349-bib-0009){ref-type="ref"} Besides SMI, individual muscle measurements, i.e. psoas muscle thickness,[10](#jcsm12349-bib-0010){ref-type="ref"} psoas muscle index (PMI),[11](#jcsm12349-bib-0011){ref-type="ref"} and psoas muscle cross‐sectional area (PMA),[12](#jcsm12349-bib-0012){ref-type="ref"}, [13](#jcsm12349-bib-0013){ref-type="ref"} have been used as indicators of increased risk of mortality in later literature. Psoas muscle assessment is easy and rapid,[11](#jcsm12349-bib-0011){ref-type="ref"} and not influenced by abdominal swelling,[10](#jcsm12349-bib-0010){ref-type="ref"} but is affected by long‐term chronic disease.[12](#jcsm12349-bib-0012){ref-type="ref"} Controversy remains regarding the use of PMI instead of SMI for the purposes of mortality risk prediction. We therefore first determined PMI association with SMI as continuous and dichotomous variables in patients with ESLD. Second, we evaluated the capability of PMI to predict mortality in patients with ESLD awaiting LT.

Methods {#jcsm12349-sec-0006}
=======

Study population {#jcsm12349-sec-0007}
----------------

Included were adult (≥18 years) patients with cirrhosis newly listed for LT (*n* = 353) from 1 January through 31 December 2012 at four North American LT centres: (i) University of California, San Francisco (141); (ii) University of Pittsburgh (*n* = 83); (iii) Mayo Clinic in Arizona (*n* = 52); and (iv) University of Alberta (77). Patients with an abdominal CT scan within 3 months of listing were included. All four centres are part of the Fitness, Life Enhancement, and Exercise in Transplantation (FLEXIT) Consortium with the ultimate goal to better understand muscle abnormalities, frailty, and their association with outcome in patients listed for LT. The study protocol was reviewed and approved by the institutional research ethics board at each centre. Clinical and demographic characteristics of the patients were collected from the medical charts at each centre. Coded, de‐identified clinical data and CT images were shared among consortium members under the terms of a formal data use agreement among the institutions.

Computed tomography image analysis {#jcsm12349-sec-0008}
----------------------------------

Skeletal muscle areas were quantified analysing L3‐CT scans by Slice‐O‐Matic software (V4.2; Tomovision, Montreal, QC, Canada) or Advantage Windows 2.2 Volume Viewer (GE Healthcare, Waukesha, WI), depending on the centre.[1](#jcsm12349-bib-0001){ref-type="ref"} Two collaborators blinded to patient outcome read the CT images. Correlation (*r*) between areas measured by two independent observers was 0.98 for both psoas and total skeletal muscle. Standard Hounsfield Unit thresholds of −29 to 150[14](#jcsm12349-bib-0014){ref-type="ref"} were used to estimate muscle cross‐sectional areas. By applying tissue‐specific radiodensity, muscle area assessments were not affected by ascites. Muscles visualized at L3 include the psoas, erector spinae, quadratus lumborum, transversus abdominis, external and internal obliques, and rectus abdominis. Cross‐sectional areas of these muscles were calculated by summing tissue pixels followed by multiplying by the pixel surface areas. Total abdominal muscle area was quantified using semi‐automatic measurement of all these muscle areas. For psoas evaluation, bilateral psoas muscle area was quantified. From L3‐CT images, we determined two muscularity variables: total skeletal muscle cross‐sectional area to establish the SMI, and psoas muscle area to determine the PMI, each normalized to the squared patient height (cm^2^/m^2^).

Statistical analysis {#jcsm12349-sec-0009}
--------------------

Continuous variables are reported as mean and standard deviation, and independent *t*‐test was used to compare means of two independent groups. Descriptive statistics for categorical variables are presented as frequency and percentages, and Pearson *χ* ^2^ test was conducted to compare study groups. Correlation between SMI and PMI was evaluated using Pearson\'s correlation coefficient (*r*) analysis. C‐statistics analysis was used to evaluate the performance of muscle cross‐sectional area, SMI, PMA, and PMI for waitlist mortality prediction.

The primary outcome of the study was waitlist mortality, described as death or delisting for being too sick for LT. In patients listed for LT, death and LT, the two competing outcomes of interest, were evaluated using competing‐risk analysis.[15](#jcsm12349-bib-0015){ref-type="ref"} Significant predictors of mortality in patients listed for LT were determined using univariate and multivariate Fine and Gray subdistribution hazards models, and the results were reported as subdistribution hazard ratios (sHRs) with 95% confidence intervals (CI). Variables with the *P* \< 0.10 in the univariate analysis were included in the multivariate model.

Cut‐offs for PMI to predict mortality were established using a receiver‐operating characteristic analysis. Model ability to differentiate between outcome groups was assessed using the area under the curve. Sex‐specific potential cut‐offs with the highest Youden\'s Index (sensitivity + specificity −1) were included in adjusted competing risk models, and the value with a highest significant *P*‐value was considered as the optimal cut‐off point. Low SMI was defined using pre‐established mortality‐associated cut‐offs in ESLD patients waiting for LT as SMI \<39 cm^2^/m^2^ in women and \<50 cm^2^/m^2^ in men.[1](#jcsm12349-bib-0001){ref-type="ref"} Potential cut‐offs for SMI in Carey *et al*.[1](#jcsm12349-bib-0001){ref-type="ref"} was calculated based on a log‐rank and Wilcoxon test statistics, followed by combination of maximized power and a significant *P*‐value. It was mentioned by previous researchers[15](#jcsm12349-bib-0015){ref-type="ref"}, [16](#jcsm12349-bib-0016){ref-type="ref"} that methods for the estimation of area under the receiver‐operating characteristic curve are primarily based on the Wilcoxon rank‐sum test and this relationship could offer a preferred level of statistical power (low type II error) in comparative experiments.

Overall survival estimates, 6 month, 1 year, and 2 year survival probabilities were obtained using Kaplan--Meier curves, and comparison between low and high PMI patients was conducted using the log‐rank test. The Cohen\'s kappa coefficient was applied to obtain agreement between SMI and PMI categories.

Results {#jcsm12349-sec-0010}
=======

Characteristics of listed patients {#jcsm12349-sec-0011}
----------------------------------

Characteristics of patients with cirrhosis listed for LT are presented in Table [1](#jcsm12349-tbl-0001){ref-type="table"}. Of 353 waitlist candidates, 70% were male with the mean age of 56 ± 9 years and Model for End‐stage Liver Disease (MELD) score of 16 ± 8 points. Mean BMI was 28 ± 6 kg/m^2^ with the majority (67%) of the patients being overweight or obese (BMI ≥ 25). Concomitant HCC was present in 41% of patients. Patients were followed to death (101), LT (170), or censoring (82).

###### 

Patient clinical characteristics by sex at the time of listing

  Characteristics                                   All Patients (*n* = 353)   Male (*n* = 246)   Female (*n* = 107)   *P* value
  ------------------------------------------------- -------------------------- ------------------ -------------------- -----------
  Age (years)                                       56 ± 9                     56 ± 9             56 ± 9               0.74
  Albumin (g/dL, 3.5--5.5)                          3 ± 2                      3 ± 1              3 ± 3                0.12
  Sodium (mmol/L, 133--146)                         135 ± 5                    134 ± 5            134 ± 6              0.35
  MELD score                                        16 ± 8                     16 ± 8             17 ± 9               0.29
  Hepatic encephalopathy                            0.73                                                               
  None                                              157 (48)                   112 (49)           45 (45)              
  Well controlled                                   156 (48)                   105 (46)           51 (51)              
  Poorly controlled                                 14 (4)                     10 (4)             4 (4)                
  Ascites                                                                                                              0.04
  None                                              131 (40)                   98 (43)            33 (33)              
  Mild                                              130 (40)                   80 (35)            50 (50)              
  Refractory                                        66 (20)                    49 (22)            17 (17)              
  HCC                                               144 (41)                   111 (44)           33 (30)              0.02
  Body composition characteristics                                                                                     
  BMI (kg/m^2^)                                     28 ± 6                     28 ± 5             27 ± 6               0.19
  PMA (cm^2^)                                       18 ± 6                     20 ± 5             13 ± 3               \<0.001
  PMI (cm^2^/m^2^)                                  6 ± 1.7                    6.5 ± 1.6          4.9 ± 1.3            \<0.001
  SMA (cm^2^)                                       129 ± 31                   154 ± 27           109 ± 22             \<0.001
  SMI (cm^2^/m^2^)                                  47 ± 9                     50 ± 8             42 ± 8               \<0.001
  VATI                                              35 ± 27                    37 ± 28            29 ± 23              0.009
  SATI                                              60 ± 40                    57 ± 37            69 ± 44              0.004
  Muscle attenuation (HU)                           36 ± 9                     37 ± 9             33 ± 9               \<0.001
  Low SMI[a](#jcsm12349-note-0004){ref-type="fn"}   165 (47)                   126 (51)           39 (36)              0.02

Numbers in parentheses are percentages.

BMI, body mass index; HCC, hepatocellular carcinoma; MELD, Model for End‐stage Liver Disease; PMA, psoas muscle area; PMI, psoas muscle index; SATI, subcutaneous adipose tissue index; SMA, skeletal muscle area; SMI, skeletal muscle index; VATI, visceral adipose tissue index.

Low SMI was defined using established cut‐offs in patients with cirrhosis listed for LT.[1](#jcsm12349-bib-0001){ref-type="ref"}

Overall mean SMI was 47 ± 9 cm^2^/m^2^ (range 23--81), and PMI was 6 ± 1.7 cm^2^/m^2^ (range 2--12). Despite similar BMI between men and women, SMI (50 ± 8 vs. 42 ± 8 cm^2^/m^2^) and PMI (6.5 ± 1.6 vs. 4.9 ± 1.3 cm^2^/m^2^) were higher in men (*P* \< 0.001 for each; Table [1](#jcsm12349-tbl-0001){ref-type="table"}). Low SMI was more frequent in men compared with women (51 vs. 36%; *P* = 0.02). SMI (39 ± 9 vs. 43 ± 7 cm^2^/m^2^; *P* = 0.009) and PMI (4.4 ± 1.3 vs. 5.2 ± 1.1 cm^2^/m^2^; *P* = 0.001) were lower in women who died and/or were delisted (compared with non‐deceased patients) whereas men who died and/or were delisted had only lower SMI (47 ± 7 vs. 51 ± 9 cm^2^/m^2^; *P* = 0.003), but not PMI compared with non‐deceased patients (Table [2](#jcsm12349-tbl-0002){ref-type="table"}). Higher proportion of the patients who died and/or were delisted had HCC at the time of listing (50% vs. 36%; *P* = 0.02). Considering differences in SMI and PMI between men and women, mortality analysis was conducted by sex.

###### 

Clinical characteristics of listed patients according to the mortality status

  Characteristics                    Died/Delisted (*n* = 101)   All others (*n* = 252)   *P* value
  ---------------------------------- --------------------------- ------------------------ -----------
  Age (years)                        57 ± 9                      55 ± 9                   0.18
  Albumin (g/dL, 3.5--5.5)           3 ± 3                       3 ± 1                    0.53
  Sodium (mmol/L, 133--146)          134 ± 5                     135 ± 6                  0.30
  MELD score                         17 ± 8                      16 ± 9                   0.38
  Hepatic encephalopathy             0.74                                                 
  None                               48 (50)                     107 (47)                 
  Well controlled                    43 (45)                     111 (49)                 
  Poorly controlled                  5 (5)                       9 (4)                    
  Ascites                                                                                 0.69
  None                               35 (36)                     94 (42)                  
  Mild                               41 (43)                     87 (38)                  
  Refractory                         20 (21)                     46 (20)                  
  HCC                                50 (50)                     91 (36)                  0.02
  Body composition characteristics                                                        
  BMI (kg/m^2^)                      27 ± 6                      28 ± 5                   0.07
  PMI (cm^2^/m^2^)                   5.5 ± 1.7                   6.2 ± 1.6                \<0.001
  SMI (cm^2^/m^2^)                   44 ± 9                      49 ± 9                   \<0.001
  Males                                                                                   
  PMI (cm^2^/m^2^)                   6.2 ± 1.6                   6.6 ± 1.6                0.12
  SMI (cm^2^/m^2^)                   47 ± 7                      51 ± 9                   0.003
  Females                                                                                 
  PMI (cm^2^/m^2^)                   4.4 ± 1.3                   5.2 ± 1.1                0.001
  SMI (cm^2^/m^2^)                   39 ± 9                      43 ± 7                   0.009

Numbers in parentheses are percentages.

BMI, body mass index; HCC, hepatocellular carcinoma; MELD, Model for End‐stage Liver Disease; PMI, psoas muscle index; SMI, skeletal muscle index.

Figure [1](#jcsm12349-fig-0001){ref-type="fig"} highlights the total skeletal muscle and psoas muscle quantification at L3 from two male patients. Figure [1](#jcsm12349-fig-0001){ref-type="fig"}A,B presents a patient who had low SMI (40 cm^2^/m^2^) but high PMI (6.6 cm^2^/m^2^). Figure [1](#jcsm12349-fig-0001){ref-type="fig"}C,D shows a patient with high SMI (54 cm^2^/m^2^) but low PMI (4.8 cm^2^/m^2^). This example illustrates that psoas muscle quantification may not necessarily reflect total muscle area assessment.

![Abdominal computed tomography images taken at the third lumbar vertebra of two male patients with cirrhosis applied to quantify total muscle and psoas muscle areas. Panels (A) and (B) present a patient who had low skeletal muscle index (SMI) (40 cm^2^/m^2^) but high psoas muscle index (PMI) (6.6 cm^2^/m^2^). Panels (C) and (D) show a patient with high SMI (54 cm^2^/m^2^) and low PMI (4.8 cm^2^/m^2^).](JCSM-9-1053-g001){#jcsm12349-fig-0001}

Association between skeletal muscle index, psoas muscle index, and waitlist mortality {#jcsm12349-sec-0012}
-------------------------------------------------------------------------------------

There was a significant linear (*P* \< 0.001) and moderately strong (*r* = 0.73) relationship between SMI and PMI in male patients (Figure [2](#jcsm12349-fig-0002){ref-type="fig"}A). Waitlist mortality prediction yielded a C‐statistic of 0.62 (95% CI 0.55--0.70, *P* = 0.004) for SMI and 0.56 (95% CI 0.48--0.65, *P* = 0.13) for PMI. The same results were obtained using areas rather than indices to predict waitlist mortality, again with a limited ability for psoas to predict mortality (Table [3](#jcsm12349-tbl-0003){ref-type="table"}). However, indices were selected as the standardized muscle values.[1](#jcsm12349-bib-0001){ref-type="ref"}, [17](#jcsm12349-bib-0017){ref-type="ref"}

![Scatter graph depicting correlations between skeletal muscle index and psoas muscle index in (A) male and (B) female patients. Using Pearson\'s correlation coefficient, moderately strong association between psoas muscle index (PMI) and skeletal muscle index (SMI) was observed in men (*r* = 0.73) and women (*r* = 0.76).](JCSM-9-1053-g002){#jcsm12349-fig-0002}

###### 

Discriminatory value of different muscle measurements in predicting waitlist mortality

  Variable   AUC    95% CI       *P* value
  ---------- ------ ------------ -----------
  Men                            
  PMA        0.56   0.48--0.65   0.15
  PMI        0.56   0.48--0.65   0.13
  SMA        0.64   0.56--0.71   0.002
  SMI        0.62   0.55--0.70   0.004
  Women                          
  PMA        0.67   0.56--0.78   0.004
  PMI        0.68   0.57--0.79   0.002
  SMA        0.65   0.53--0.76   0.01
  SMI        0.66   0.55--0.77   0.007

AUC, area under the ROC curve; CI, confidence interval; PMA, psoas muscle area; PMI, psoas muscle index; SMA, skeletal muscle area; SMI, skeletal muscle index.

In univariate analysis, assessing the association between clinical parameters and outcome, SMI, as a continuous variable, was significantly associated with waitlist mortality (sHR 0.96, 95% CI 0.93--0.98, *P* \< 0.001; Table [4](#jcsm12349-tbl-0004){ref-type="table"}A). Considering LT as the competing event, SMI was independently associated with mortality after adjusting for MELD score and HCC (sHR 0.95, 95% CI 0.92--0.98, *P* = 0.001; SMI‐Model, Table [4](#jcsm12349-tbl-0004){ref-type="table"}A). Using pre‐established mortality‐associated cut‐offs for SMI, male patients with low SMI, as a categorical variable, had more than two‐fold higher mortality risk after adjusting for recognized mortality predictors (sHR 2.46, 95% CI 1.38--4.39, *P* = 0.002; SMI‐Model, Table [5](#jcsm12349-tbl-0005){ref-type="table"}A).

###### 

Clinical parameters associated with mortality in listed patients according to sex

                           Univariate analysis   Multivariate analysis                                                   
  ------------------------ --------------------- ----------------------- ------------------- ------- ------------------- -------
  A. Male Patients                                                                                                       
  Age (years)              1.02 (0.99--1.06)     0.21                                                                    
  Albumin (g/dL)           0.80 (0.51--1.25)     0.32                                                                    
  MELD score               1.01 (0.98--1.04)     0.45                    1.01 (0.98--1.05)   0.52    1.02 (0.98--1.05)   0.32
  Ascites                  1.22 (0.87--1.70)     0.25                                                                    
  Sodium (mmol/L)          0.97 (0.93--1.01)     0.13                                                                    
  HCC                      1.76 (1.07--2.90)     0.03                    2.16 (1.19--3.91)   0.01    1.93 (1.08--3.44)   0.03
  Hepatic encephalopathy   1.05 (0.67--1.65)     0.82                                                                    
  SMI (cm^2^/m^2^)         0.96 (0.93--0.98)     \<0.001                 0.95 (0.92--0.98)   0.001                       
  PMI (cm^2^/m^2^)         0.86 (0.73--1.02)     0.08                                                0.85 (0.70--1.03)   0.09
  B. Female patients                                                                                                     
  Age (years)              1.01 (0.98--1.05)     0.55                                                                    
  Albumin (g/L)            1.02 (0.997--1.05)    0.07                    0.74 (0.42--1.31)   0.30    0.75 (0.44--1.27)   0.29
  MELD score               1.02 (0.99--1.05)     0.25                    1.00 (0.97--1.04)   0.69    1.00 (0.97--1.04)   0.73
  Ascites                  0.90 (0.63--1.30)     0.59                                                                    
  Sodium (mmol/L)          0.99 (0.95--1.04)     0.82                                                                    
  HCC                      1.45 (0.80--2.65)     0.22                                                                    
  Hepatic encephalopathy   0.93 (0.51--1.68)     0.80                                                                    
  SMI (cm^2^/m^2^)         0.94 (0.90--0.99)     0.01                    0.94 (0.89--1.00)   0.048                       
  PMI (cm^2^/m^2^)         0.59 (0.44--0.79)     \<0.001                                             0.58 (0.41--0.82)   0.002

sHRs and *P* values were estimated using Fine‐Gray subdistribution hazard model.

CI, confidence interval; HCC, hepatocellular carcinoma; MELD, Model for End‐stage Liver Disease; PMI, psoas muscle index; sHR, subdistribution hazard ratio; SMI, skeletal muscle index.

###### 

Association of low SMI and low PMI with mortality in listed patients according to sex

                                                    Univariate analysis   Multivariate analysis                                                   
  ------------------------------------------------- --------------------- ----------------------- ------------------- ------- ------------------- ------
  A. Male patients                                                                                                                                
  MELD score                                        1.01 (0.98--1.04)     0.45                    1.02 (0.99--1.06)   0.22    1.02 (0.99--1.05)   0.26
  HCC                                               1.76 (1.07--2.90)     0.03                    2.18 (1.22--3.89)   0.008   1.98 (1.12--3.49)   0.02
  Low SMI[a](#jcsm12349-note-0013){ref-type="fn"}   2.17 (1.29--3.66)     0.003                   2.46 (1.38--4.39)   0.002                       
  Low PMI[b](#jcsm12349-note-0014){ref-type="fn"}   1.85 (1.05--3.24)     0.03                                                2.04 (1.13--3.68)   0.02
  B. Female patients                                                                                                                              
  MELD score                                        1.02 (0.99--1.05)     0.25                    1.00 (0.97--1.04)   0.82    1.01 (0.98--1.05)   0.47
  Albumin (g/dL)                                    1.02 (0.997--1.05)    0.07                    0.79 (0.44--1.41)   0.42    0.77 (0.43--1.36)   0.36
  Low SMI[a](#jcsm12349-note-0013){ref-type="fn"}   2.12 (1.14--3.93)     0.02                    2.05 (1.00--4.21)   0.050                       
  Low PMI[b](#jcsm12349-note-0014){ref-type="fn"}   2.45 (1.32--4.58)     0.005                                               2.47 (1.24--4.95)   0.01

sHRs and *P* values were estimated using Fine‐Gray subdistribution hazard model.

Variables with a *P* \< 0.10 of Table [2](#jcsm12349-tbl-0002){ref-type="table"} are included in multivariable model.

CI, confidence interval; MELD, Model for End‐stage Liver Disease; PMI, psoas muscle index; sHR, subdistribution hazard ratio; SMI, skeletal muscle index.

Low SMI was defined using established cut‐offs in patients with cirrhosis.[1](#jcsm12349-bib-0001){ref-type="ref"}

Defined as PMI \< 5.1 cm^2^/m^2^ in men and PMI \< 4.3 cm^2^/m^2^ in women.

Psoas muscle index (cm^2^/m^2^), as a continuous variable, demonstrated a trend towards negative association with mortality in both univariate (sHR 0.86, 95% CI 0.73--1.02, *P* = 0.08) and multivariate models (sHR 0.85, 95% CI 0.70--1.03, *P* = 0.09; Table [4](#jcsm12349-tbl-0004){ref-type="table"}A). Every 1 cm^2^/m^2^ increase in PMI tended to be associated with 15% decreased risk of death. Applying the highest Youden\'s Index, PMI of 5.1 cm^2^/m^2^ was found to be independently associated with mortality with a sensitivity of 84%. Male patients with PMI \<5.1 cm^2^/m^2^ had a two times higher risk of mortality (HR 2.04, 95% CI 1.13--3.68, *P* = 0.02; PMI‐Model, Table [5](#jcsm12349-tbl-0005){ref-type="table"}A) compared with the patients with high PMI (≥5.1 cm^2^/m^2^). The 6 month, 1 year, and 2 year probabilities of survival were 80%, 59%, and 54% in patients with low PMI compared with 88%, 83%, and 68% in men with high PMI (log rank = 0.02) (Figure [3](#jcsm12349-fig-0003){ref-type="fig"}A).

![Survival curves in (A) male and (B) female patients with high and low psoas muscle index. Survival over time was estimated using Kaplan--Meier curves, and the curves were compared using the log‐rank test. Longer survival was observed in patients with high psoas muscle index (PMI) compared with the patients with low PMI (log rank, *P* = 0.02 and *P* = 0.002 in men and women, respectively).](JCSM-9-1053-g003){#jcsm12349-fig-0003}

We observed a moderately strong (*r* = 0.76) linear (*P* \< 0.001) correlation between SMI and PMI in female patients (Figure [2](#jcsm12349-fig-0002){ref-type="fig"}B). The ability of the SMI and PMI to rank patients according to waitlist mortality (i.e. C‐statistic) were 0.66 (95% CI 0.55--0.77, *P* = 0.007) and 0.68 (95% CI 0.57--0.79, *P* = 0.002), respectively (Table [3](#jcsm12349-tbl-0003){ref-type="table"}).

Univariate and multivariate competing risk analysis of features associated with mortality were conducted in female patients listed for LT. Albumin, MELD score, SMI, and PMI were predictors of mortality in women in the univariate analysis (Table [4](#jcsm12349-tbl-0004){ref-type="table"}B). There was a negative association between SMI (cm^2^/m^2^) and mortality in multivariate models (sHR 0.94, 95% CI 0.89--1.00, *P* = 0.048). PMI (cm^2^/m^2^) was significantly negatively associated with mortality in multivariate models (sHR 0.58, 95% CI 0.41--0.82, P = 0.002) (Table [4](#jcsm12349-tbl-0004){ref-type="table"}B). In a multivariate model including confounding clinical variables, low SMI increased by two‐fold the risk of mortality in female patients (sHR 2.05, 95% CI 1.00--4.21, *P* = 0.05; SMI‐Model, Table [5](#jcsm12349-tbl-0005){ref-type="table"}B) compared with patients with high SMI. In women, PMI of 4.3 cm^2^/m^2^ was found to yield the highest Youden\'s Index, with the sensitivity of 78% and area under the curve of 0.68 (95% CI 0.57--0.79). Low PMI (PMI \<4.3 cm^2^/m^2^) was an independent predictor of elevated mortality (sHR 2.47, 95% CI 1.24--4.95, *P* = 0.01), after adjusting for other survival predictors (PMI‐Model, Table [5](#jcsm12349-tbl-0005){ref-type="table"}B). Kaplan--Meier analysis to calculate survival probability based on psoas muscle cut‐offs revealed that the 6 month, 1 year, and 2 year probabilities of survival were 63%, 47%, and 34% in patients with low PMI compared with 85%, 75%, and 62% in women with high PMI (log rank = 0.002) (Figure [3](#jcsm12349-fig-0003){ref-type="fig"}B).

Concordance between skeletal muscle index and psoas muscle index categories {#jcsm12349-sec-0013}
---------------------------------------------------------------------------

Of all male patients with low SMI, only 34% were categorized as low based on the PMI (Table [6](#jcsm12349-tbl-0006){ref-type="table"}). The Kappa coefficient for the agreement between low SMI and low PMI was 0.31 (*P* \< 0.001; Table [6](#jcsm12349-tbl-0006){ref-type="table"}), demonstrating a poor agreement between the two assessments. In women, 72% of those classified as low SMI were classified in low PMI group. The agreement estimated by the Kappa coefficient was 0.63 in women indicating a moderate agreement between the two assessments. Overall, 104 patients (29%) were misclassified between SMI and PMI categories (Table [6](#jcsm12349-tbl-0006){ref-type="table"}). No significant difference regarding age (56 ± 9 vs. 55 ± 10; *P* = 0.42), HCC (34% vs. 41%, *P* = 0.19), ascites (62% vs. 59%, *P* = 0.13), and albumin (3 ± 2 vs. 3 ± 1 g/dL; *P* = 0.65) was observed between a misclassified group of patients and those who were correctly classified. Male patients were more likely to be misclassified (35% vs. 17%, *P* = 0.001), and MELD score was lower in misclassified patients (16 ± 7 vs. 18 ± 10 cm^2^/m^2^; *P* = 0.03).

###### 

Concordance between SMI and PMI categories

                               Male patients   Female patients             
  ---------------------------- --------------- ----------------- --------- ---------
  Low PMI                      43 (34)         3 (3)             28 (72)   7 (10)
  High PMI                     83 (66)         117 (97)          11 (28)   61 (90)
  Kappa coefficient (95% CI)   0.31            0.63                        
  0.22--0.41                   0.47--0.77                                  
  *P* value                    \<0.001         \<0.001                     

CI, confidence interval; PMI, psoas muscle index; SMI, skeletal muscle index.

Kappa coefficient was used to assess the agreement between two assessments.

Low PMI was defined as PMI \< 5.1 cm^2^/m^2^ in men and PMI \< 4.3 cm^2^/m^2^ in women.

Numbers in parentheses are percentages.

Discussion {#jcsm12349-sec-0014}
==========

The prevalence of sarcopenia, defined as low SMI, in cirrhosis ranges between 22% and 70% according to CT studies,[18](#jcsm12349-bib-0018){ref-type="ref"} with higher prevalence in men.[4](#jcsm12349-bib-0004){ref-type="ref"}, [6](#jcsm12349-bib-0006){ref-type="ref"} SMI has been shown to be a reliable indicator of total body muscle mass,[8](#jcsm12349-bib-0008){ref-type="ref"}, [9](#jcsm12349-bib-0009){ref-type="ref"} and predictor of mortality in patients with cirrhosis,[4](#jcsm12349-bib-0004){ref-type="ref"}, [6](#jcsm12349-bib-0006){ref-type="ref"} and in patients listed for LT.[1](#jcsm12349-bib-0001){ref-type="ref"} Currently, there is a discrepancy in the literature regarding sarcopenia quantification and definition in cirrhosis. This demonstrates the necessity to develop a standardized definition of sarcopenia that can be implemented in other LT centres. The authors have started a consortium of LT centres to develop a comprehensive data set and reach consensus to perform the muscularity assessment in a uniform fashion. To date, this data set is the only North American study to define sarcopenia using data derived from a diverse population of LT candidates, which has been implemented in this study.

Sarcopenia associates with various clinical complications in aging[19](#jcsm12349-bib-0019){ref-type="ref"}, [20](#jcsm12349-bib-0020){ref-type="ref"}, [21](#jcsm12349-bib-0021){ref-type="ref"}, [22](#jcsm12349-bib-0022){ref-type="ref"} and cachexia‐associated chronic diseases[3](#jcsm12349-bib-0003){ref-type="ref"}, [23](#jcsm12349-bib-0023){ref-type="ref"}, [24](#jcsm12349-bib-0024){ref-type="ref"}, [25](#jcsm12349-bib-0025){ref-type="ref"}, [26](#jcsm12349-bib-0026){ref-type="ref"}; therefore, sensitive and reproducible measures of muscle mass are required to assess the evolution of muscle loss and to follow outcomes of therapeutic interventions[26](#jcsm12349-bib-0026){ref-type="ref"}, [27](#jcsm12349-bib-0027){ref-type="ref"} directed at attenuation of tissue loss in order to improve outcome of patients. Considering availability of diagnostic CT scans in the majority of cachexia‐associated disease such as cancer and cirrhosis, as well as high accuracy and time efficacy of different software programmers[28](#jcsm12349-bib-0028){ref-type="ref"} for body composition measurements, finding an appropriate indicator of muscle mass, i.e. total muscle or psoas, should be the priority in cachexia context.

This study aimed to investigate whether low PMI can be applied as a representative surrogate of low SMI for predicting waitlist mortality in patients with cirrhosis. A moderately strong correlation between SMI and PMI as continuous variables was observed; however, categorizing PMI yielded poor and moderate concordance with SMI in men and women, respectively. Our data show that PMI has a poor capacity to identify patients with higher waitlist mortality in cirrhosis. A significant proportion of patients with higher waitlist mortality risk might be underestimated in men using PMI cut‐offs, as more than half of men with low SMI (66%) were categorized as having high PMI with an implied lower mortality risk. Poor agreement (Kappa coefficient = 0.31) between the two assessments accounted for the different proportions of patients in each category. Moreover, among men, the cut‐off for SMI values identified a 51% of participants into the low muscle mass group. Conversely, the threshold that was identified as most statistically optimal for PMI only classifies 19% of the men as low muscle, which is a large discrepancy, and results are in poor concordance. Moreover, it is not only the selected PMI cut‐offs that perform poorly, but also when PMI was evaluated as a continuous variable in relation to mortality risk and the mean of died/delisted group was compared with all others, it was not as effective as SMI in men. As a consequence, it is not only the stratification strategy used that is flawed but also that analysis of PMI is not as good a metric as SMI, in men. Therefore, patients with a higher risk of mortality would incorrectly be classified as low risk and given the importance of sarcopenia in predicting mortality of men with cirrhosis; PMI should not be used to substitute SMI to predict mortality. Greater predictive accuracy and robustness of SMI compared with that of PMI appears to be biologically plausible because SMI takes into account a larger proportion of total muscle mass than does PMI.

Although sarcopenia is not a current criterion for expedited LT, giving some priority to those patients with sarcopenia may help to decrease mortality in a subgroup of patients with cirrhosis.[3](#jcsm12349-bib-0003){ref-type="ref"}, [29](#jcsm12349-bib-0029){ref-type="ref"} Sarcopenia is one of the major manifestations of protein‐energy malnutrition in cachexia‐associated diseases, and to prevent adverse clinical implications, early and proper identification of patients with sarcopenia should be implanted and intense nutritional and physical interventions should be included to improve patient conditions and to lessen mortality risk in patients with higher risk as determined by low SMI.

In women, the cut‐off for PMI‐associated mortality was at the 33rd percentile of calculated PMI, and subsequently, 33% of women fell into the high‐risk group. This result is similar to 33% of women with low SMI, below the established cut‐off previously reported by our group.[1](#jcsm12349-bib-0001){ref-type="ref"} Although Kappa coefficient showed good agreement between two assessments in women (0.63), there might still be some misclassification as 28% of women with low SMI and higher mortality risks were placed in the high‐PMI category. We speculate that psoas muscle in women with cirrhosis is preferentially depleted in sarcopenia, whereas muscles other than psoas might be affected at greater intensity in men. The exact mechanism behind this association has not been elucidated. However, a study in post‐menopausal women enrolled in a weight loss training programme showed that muscle was mainly lost from psoas and erector spine areas but not from lateral abdominal area and rectus abdominis.[30](#jcsm12349-bib-0030){ref-type="ref"} Moreover, it has been described by other researchers that noticeable decline in female psoas muscle area may be due to post‐menopausal hormonal changes.[31](#jcsm12349-bib-0031){ref-type="ref"} This emphasizes the necessity for longitudinal studies to investigate potential loss of PMI and SMI stratified by sex.

The psoas is a key muscle for posture and core strength,[32](#jcsm12349-bib-0032){ref-type="ref"} which might represent sarcopenia better than other individual anthropometric muscle measurements, such as triceps thickness;[17](#jcsm12349-bib-0017){ref-type="ref"} however, it only accounts for approximately 13% of total skeletal muscle area at the level of L3 in our population. Psoas muscle mass in an individual patient might also be affected by other conditions such as degenerative spine disease and chronic low back pain,[33](#jcsm12349-bib-0033){ref-type="ref"} both common conditions in an older population and potentially selective for psoas muscle loss compared with loss of total musculature.

Studies evaluating the association between psoas muscle and mortality in various populations have yielded inconsistent results.[10](#jcsm12349-bib-0010){ref-type="ref"}, [11](#jcsm12349-bib-0011){ref-type="ref"}, [12](#jcsm12349-bib-0012){ref-type="ref"}, [34](#jcsm12349-bib-0034){ref-type="ref"}, [35](#jcsm12349-bib-0035){ref-type="ref"} Discrepancy may arise because of disparate techniques and measurements of psoas muscle, such as PMA, PMI (normalized to patient squared height),[11](#jcsm12349-bib-0011){ref-type="ref"} right psoas thickness at the level of umbilicus,[10](#jcsm12349-bib-0010){ref-type="ref"} short‐axis to long‐axis ratios of the right and left psoas muscles[36](#jcsm12349-bib-0036){ref-type="ref"} that have been applied to predict clinical outcomes. Because of the asymmetrical shape of psoas muscle, validity and reliability of some of those approaches could be questioned.[37](#jcsm12349-bib-0037){ref-type="ref"} Despite a strong association between sarcopenia, measured by total psoas area, with post‐transplant mortality, variations in total psoas areas in patients undergoing LT led to extreme variation in mortality risk following LT.[12](#jcsm12349-bib-0012){ref-type="ref"}

Overall, data regarding the use of PMI instead of SMI for the purposes of mortality risk prediction in cirrhosis are limited. Among various muscle measurements, i.e. PMA, PMI, and SMI at L3, to predict post‐LT mortality in 256 transplanted patients, PMA was selected as the simplest measure with the highest accuracy.[13](#jcsm12349-bib-0013){ref-type="ref"} Using sex‐specific cut‐off values for PMA (1561 mm^2^ in men, 1464 mm^2^ in women), 22% of the patients were identified as sarcopenic (below cut‐off for PMA) with poorer survival,[13](#jcsm12349-bib-0013){ref-type="ref"} whereas in our previous experience[1](#jcsm12349-bib-0001){ref-type="ref"} using SMI cut‐offs (50 cm^2^/m^2^ in men, 39 cm^2^/m^2^ in women), 50% of men and 33% of women exhibited higher waitlist mortality associated with low SMI. Therefore, comparison between studies is limited by divergent outcomes, post‐LT mortality in patients undergoing LT[12](#jcsm12349-bib-0012){ref-type="ref"}, [13](#jcsm12349-bib-0013){ref-type="ref"} vs. waitlist mortality in listed patients,[1](#jcsm12349-bib-0001){ref-type="ref"} which may contribute to inconsistent results.

Abdominal total skeletal muscle and psoas muscle assessment by CT images in patients with ESLD listed for LT is the main strength of this multicentre study. Moreover, we evaluated mortality risk by competitive risk analysis with LT as the competitive event. Applying competing‐risk analysis, rather than conventional survival analysis, is a more robust approach in the presence of competing event.[38](#jcsm12349-bib-0038){ref-type="ref"} Patients were included from four North American LT centres with standardized inclusion criteria to ensure homogeneous patient population. We acknowledge limitations of the present study, as we could not include patients without an available CT for muscularity assessment. Also, we were unable to evaluate muscle quality and muscle strength because of the retrospective nature of the study.

In conclusion, CT‐defined PMI cut‐off predicts waitlist mortality in patients with cirrhosis but identifies only an incomplete subset of those at increased risk of mortality indicated by low SMI. Therefore, we propose that SMI is a more complete and robust measurement, especially in men with cirrhosis, and given the poor performance of PMI, SMI should not be substituted by PMI. Transferability of the results to clinical settings requires consensus and more specific definition of muscle abnormalities including both muscle mass and quality in ESLD patients.
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